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19 Studies on the prevalence and diversity of Clostridium difficile in Thailand have been 
20 limited to those derived from a few tertiary hospitals in Central Thailand. In this study, 145 
21 C. difficile isolates collected in 13 provinces in Thailand during 2006-2018 were 
22 characterized by ribotyping and detection of toxin genes. Minimum inhibitory 
23 concentrations of eight antimicrobial agents were determined also for all 100 C. difficile 
24 strains collected from 2006 until 2015. Of the 145 strains of C. difficile, 71 (49%) were non-
25 toxigenic, 46 (32%) were toxin A-negative, toxin B-positive (A-B+) and 28 (19%) were A+B+. 
26 No binary toxin-positive strain was found. The most common ribotype (RT) was RT 017 (A-
27 B+CDT-, 19%, 28/145). Besides RT 017, 20 novel non-toxigenic and A-B+ ribotyping profiles, 
28 which may be related to RT 017 by the similarity of ribotyping profile, were identified. All 
29 C. difficile strains remained susceptible to metronidazole and vancomycin, however, a slight 
30 increase in MIC for metronidazole was seen in both toxigenic and non-toxigenic strains 
31 (overall MIC50/90 0.25/0.25 mg/L during 2006 – 2010 compared to overall MIC50/90 1.0/2.0 
32 mg/L during 2011 – 2015). There was a high rate of fluoroquinolone resistance among RT 
33 017 strains (77%), but there was little resistance among non-toxigenic strains. These results 
34 suggest that RT 017 is endemic in Thailand, and that the misuse of fluoroquinolones may 
35 lead to outbreaks of RT 017 infection in this country. Further studies on non-toxigenic C. 
36 difficile are needed to understand whether they have a role in the pathogenesis of C. difficile 
37 infection in Asia.
38




41 Clostridium difficile is an important cause of hospital-associated diarrhea with 
42 symptoms ranging from self-limiting watery diarrhea to life-threatening colitis (1, 2). 
43 C. difficile infection (CDI) occurs when the stability of intestinal microbiota is disturbed, 
44 often by exposure to antimicrobial agents, allowing C. difficile spores to germinate, multiply 
45 and eventually cause disease (1). CDI is mediated mainly by toxins and, to date, three toxins 
46 have been identified as the major virulence factors: toxin A (TcdA), toxin B (TcdB) and binary 
47 toxin (CDT) (3, 4). 
48 C. difficile can be classified into different ribotypes (RTs) based on the banding 
49 patterns produced by PCR of the intergenic spacer region between the 16S and 23S rRNA 
50 genes (5). Previous studies in Bangkok, Thailand (6, 7), reported a high prevalence of 
51 C. difficile RT 017, a toxigenic strain of C. difficile with a deletion in the repeating region of 
52 the tcdA gene, resulting in a non-functional toxin A (A-B+CDT- C. difficile) (8). Another recent 
53 study found a high prevalence of A-B+CDT- C. difficile in two different regions of Thailand, 
54 but ribotyping was not performed (9).
55 C. difficile RT 017 has been associated with high rates of antimicrobial resistance, 
56 which may have facilitated its successful spread globally and promoted outbreaks in the 
57 past (10-14). In Thailand, RT 017 has also been associated with an accumulation of 
58 antimicrobial resistance in addition to reports of multidrug-resistant non-toxigenic 
59 C. difficile strains which may serve as a reservoir for accessory resistance genes (15).
60 Previously, knowledge of C. difficile in Thailand was limited to a few major hospitals 
61 in Bangkok. This study aimed to describe the strains of C. difficile found in other parts of the 
62 country. The National Institute of Health, Department of Medical Sciences, Ministry of 
ACCEPTED MANUSCRIPT
4
63 Public Health, Thailand (TH-NIH) is a reference laboratory that receives faecal specimens for 
64 C. difficile culture from medical centres, and secondary and tertiary hospitals, in various 
65 regions of Thailand. The TH-NIH has the largest collection of C. difficile strains in Thailand. 
66 Using this collection, which included some strains from a previous study that had not been 
67 ribotyped (9), we hoped to report on the diversity of C. difficile throughout Thailand. 
68 Materials and Methods
69 Study sites and C. difficile isolates
70 C. difficile strains used in this study were cultured at the TH-NIH. When requested for 
71 C. difficile culture, a faecal specimen was collected and sent to the TH-NIH at 4 °C within 24 
72 h. Upon arrival, specimens were treated with absolute ethanol at a 1:1 ratio for 1 h before 
73 inoculation onto Wilkins-Chalgren blood agar (CM 619B; Oxoid England). All agar plates 
74 were incubated anaerobically at 37 °C for 48 h and putative C. difficile colonies tested for 
75 phenotypic properties consistent with C. difficile (glucose and fructose fermentation, the 
76 presence of gelatinase and the positive result on esculin hydrolysis test). C. difficile ATCC 
77 43255 (A+B+CDT-, RT 087) was used as a control strain. For long-term storage, all C. difficile 
78 strains were suspended in 2 mL of 15 % glycerol broth and kept at - 70 °C. A total of 145 
79 C. difficile strains from clinical specimens processed from January 2006 to January 2018 
80 were available in the TH-NIH collection. The strains were originally from the regions 
81 highlighted in Figure 1. For this study, C. difficile strains were inoculated on Wilkins-Chalgren 
82 blood agar and incubated anaerobically at 37 °C for 48 h before DNA extraction. DNA from 
83 all C. difficile strains was extracted using the NucleoSpin® tissue extraction kit (Macherey-
84 Nagel, Germany). PCR for the tpi gene was initially done on all DNA samples to ensure the 
85 adequate quality of DNA using primers published by Lemee et al. (16). All DNA samples were 
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86 further sent to a reference laboratory in Western Australia for toxin gene detection and PCR 
87 ribotyping.
88 Toxin gene detection and PCR ribotyping
89 At the reference laboratory, all strains were tested for the presence of toxin A (tcdA), 
90 toxin B (tcdB) and binary toxin (cdtA and cdtB) genes, and PCR ribotyped, as previously 
91 described (5, 17-19). Ribotypes were identified by comparison of the band profiles with our 
92 reference library, that consisted of a collection of >50 ribotypes that included 15 reference 
93 strains from the European Centre for Disease Prevention and Control and the most 
94 prevalent PCR ribotypes currently circulating in Australia (T. V. Riley et al., unpublished 
95 data). Strains that did not match the reference strains but had been previously described in 
96 our laboratory were given the internal nomenclature prefix"QX". Novel strains found in this 
97 study were given the prefix "KI".
98 Antimicrobial susceptibility testing
99 Antimicrobial susceptibility testing (AST) results were retrieved from the TH-NIH 
100 database. Minimal inhibitory concentrations (MICs) for eight antimicrobial agents 
101 (vancomycin, metronidazole, clindamycin, moxifloxacin, levofloxacin, tetracycline, 
102 erythromycin and chloramphenicol) were determined for all 100 C. difficile strains isolated 
103 during 2006 – 2015 using the agar dilution method as recommended by the Clinical and 
104 Laboratory Standard Institute (CLSI) (20). MIC breakpoints for metronidazole and 
105 vancomycin were based on the European Committee on Antimicrobial Susceptibility Testing 
106 (EUCAST) recommendations (21). MIC breakpoints for clindamycin, moxifloxacin, 
107 tetracycline and chloramphenicol were based on CLSI recommendations (20) while the MIC 
108 breakpoint for erythromycin was based on a previous publication (15). There were no 
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109 available MIC breakpoints for levofloxacin and so MIC50 and MIC90 values for this 
110 antimicrobial were used to compare the susceptibility of C. difficile strains.
111 Results
112 High prevalence of non-toxigenic and A-B+CDT- C. difficile in Thailand
113 Table 1 summarises ribotypes and toxin gene profiles of C. difficile strains 
114 investigated in this study. Seventy-one strains (49%) were negative for all three toxin genes 
115 by PCR (A-B-CDT-). Among the 74 toxigenic strains, 46 (62%) were A-B+CDT- C. difficile while 
116 28 (38%) were A+B+CDT- C. difficile. No binary toxin-positive C. difficile was found in this 
117 study. Table 2 shows the different distribution of common RTs in different regions of 
118 Thailand.
119 Forty different C. difficile RTs were found in this study (Table 1). Only five RTs 
120 matched reference strains from the ECDC, seven had been previously described in our 
121 laboratory reference database (nomenclature "QX") and 28 had not been previously 
122 described (nomenclature "KI"). The most common RT was C. difficile RT 017 (A-B+CDT-) 
123 [19%; 28/145], followed by the non-toxigenic RTs QX 578 [12%; 18/145], RT QX 500 [9%; 
124 13/145] and RT QX 021 [8%; 11/145]. The most common A+B+CDT- C. difficile belonged to 
125 RT 014/020 [7%; 10/145].
126 Besides C. difficile RT 017, 13 new A-B+CDT- RTs were identified in this study. All A-
127 B+CDT- C. difficile strains in this study were positive for the non-repeating region of tcdA 
128 gene but negative for the repeating region of tcdA gene (Figure 2).
129 Different C. difficile strains had very similar ribotyping pattern
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130 Many novel RTs had ribotyping patterns similar to the RTs previously described. 
131 Among these, several C. difficile strains had similar patterns to RT QX 578 (A-B-CDT-) which 
132 are demonstrated in Figure 3.  However, these strains of C. difficile had different toxin 
133 profiles (1 A+B+CDT- strain, 3 A-B+CDT- strains and 2 non-toxigenic strains). Besides these 
134 RTs, five RTs were similar to RT QX 108 and two RTs were similar to RT 017.
135 All C. difficile remained susceptible to metronidazole and vancomycin 
136 Overall MIC and susceptibility data of 100 C. difficile strains from Thailand is shown 
137 in Table 3. All C. difficile were susceptible to metronidazole and vancomycin. Ninety-one 
138 C. difficile strains were resistant to clindamycin, while 31 were resistant to moxifloxacin, 28 
139 of which also had high MIC levels (≥ 64 mg/L) of levofloxacin. Most strains remained 
140 susceptible to tetracycline and chloramphenicol (82% and 88%, respectively). MIC50 and 
141 MIC90 for eight antimicrobials against C. difficile by different toxin gene profiles are shown in 
142 Table 4. A-B+CDT- C. difficile had higher MIC50 values for clindamycin, moxifloxacin and 
143 levofloxacin compared to other C. difficile strains.
144 Fewer C. difficile RT 017 strains were susceptible to fluoroquinolones and tetracycline
145 Susceptibility profiles of common C. difficile RTs are shown in Table 5. A smaller 
146 proportion of C. difficile RT 017 strains was susceptible to moxifloxacin compared to other 
147 RTs (23% vs 72%; Chi-square p < 0.001). This RT also had higher MIC50 and MIC90 values for 
148 levofloxacin (128 mg/L and 128 mg/L, respectively) compared to other RTs (4 mg/L and 128 
149 mg/L, respectively). C. difficile RT 017 also appeared to be less susceptible to tetracycline 




152 The high prevalence of C. difficile RT 017 in this study is supported previous 
153 publications suggesting that RT 017 is endemic in South East Asia. C. difficile RT 017 has 
154 been reported as the most prevalent toxigenic RT of C. difficile in other South East Asian 
155 countries such as Indonesia and Malaysia (22-24) and is commonly found in China (25) and 
156 South Korea (26). In two previous studies in Thailand, RT 017 was also among the most 
157 prevalent toxigenic strains (6, 7). Besides the high prevalence of RT 017, we also found 13 
158 novel toxigenic C. difficile RTs with a deletion in the repeating region of tcdA gene (A-B+CDT-
159 ). This characteristic has been described previously in C. difficile closely related to RT 017 
160 (27-31), suggesting that these novel RTs may also be related to RT 017. A whole genome 
161 sequence (WGS) analysis will be needed to confirm the relatedness of new RT 017-like 
162 isolates to RT 017.
163 C. difficile RT 017 belongs to the multilocus sequence type (MLST) clade 4 of 
164 C. difficile (28). It is believed that C. difficile diverged into different clades millions of years 
165 ago and prior to the acquisition of the pathogenicity locus (PaLoc) region of the genome 
166 that contains the genes for toxins A and B. PaLoc acquisition has subsequently occurred at 
167 different times in different geographical areas of the world (28). Clade 4 consists mainly of 
168 non-toxigenic and A-B+CDT- C. difficile strains (27-31), similar to what was found in the 
169 present study and several previous studies of C. difficile in South East Asia (7, 22-24).  These 
170 consistent findings of C. difficile RT 017 endemicity in South East Asia and the significant 
171 diversity of other clade 4 strains implies that the origin of RT 017 and clade 4 is in this region 
172 and not North America as reported by Cairns et al. (32). In order to confirm that these 
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173 C. difficile strains are related to RT 017 and belong in the same clade, MLST will be required 
174 following WGS.
175 PCR ribotyping has been used globally in prevalence studies to determine strain 
176 relatedness due to its simplicity (33). It is also used in Europe for CDI surveillance purposes 
177 (34), however, its limitations should be noted (35, 36). This study reports several novel 
178 C. difficile RTs with similar ribotyping patterns, as demonstrated in Figure 3. Some banding 
179 patterns were almost indistinguishable from one another highlighting the limits in 
180 discriminatory power of this method. Also, similar banding patterns do not guarantee strain 
181 relatedness as the banding pattern relies mainly on differences in PCR amplicon size, not the 
182 actual nucleotide sequence. The use of toxin gene profiles can help further classify these 
183 strains, however, other methods, such as MLST and/or whole genome sequencing (WGS), 
184 are needed to confirm strain relatedness.
185 Though the number of strains from some parts of Thailand was low, some 
186 differences in the distribution of C. difficile can be seen (Table 2). In the Northern region, 
187 there was a higher prevalence of A+B+CDT- C. difficile, primarily RT 014/020, and lower 
188 prevalence of non-toxigenic strains. In the Western region, there was a lower prevalence of 
189 A-B+CDT- C. difficile and no RT 017 was found. Notably, the prevalence of C. difficile in a 
190 large tertiary hospital in Central Thailand in previous studies was different from the 
191 prevalence found in this study. The previous studies reported a high prevalence of RT 
192 014/020 (6, 7), similar to that found in Northern Thailand in this study. Given the marked 
193 increase in the prevalence of C. difficile RT 014/020 between two study periods (25% during 
194 2006 – 2008 to 44% in 2015), it is possible that there was an outbreak of RT 014/020 
195 infection during the previous studies (6, 7). Strains from Northern Thailand in the present 
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196 study also came from a single tertiary hospital and the high prevalence of RT 014/020 could 
197 also be due to an outbreak. Also, Chiang Rai is one of the top tourist destinations in 
198 Thailand, attracting significant numbers of tourists from Europe, and this may have 
199 impacted on the appearance of C. difficile RT 014/020 in the community 
200 (https://www.mots.go.th/mots_en57/more_news.php?cid=332&filename=index).
201 Though the high prevalence of non-toxigenic C. difficile was consistent with previous 
202 studies, the RTs and antimicrobial susceptibility patterns were different (15). The most 
203 common non-toxigenic C. difficile strains in a previous study belonged to RTs 010 (11%; 
204 12/105), 039 (9%; 9/105) and 009 (6%; 6/105). Only one RT 010 and no RTs 039 and 009 
205 were identified in this study, and the three most common non-toxigenic RTs had rarely been 
206 isolated in the previous studies. Only one RT QX 578 had been isolated in the Southern part 
207 of Thailand in 2014 (Collins DA, unpublished data), RT QX 021 was previously found in 5% of 
208 C. difficile in Malaysia (22) and no RT QX 500 had been isolated in South East Asia before. It 
209 appears that the population of non-toxigenic C. difficile in South East Asia is more diverse 
210 than previously thought. Given that non-toxigenic C. difficile may have a protective role 
211 against the development of CDI which could result in a lower prevalence and severity of 
212 disease in the region (37-39), further studies should be conducted on these non-toxigenic 
213 strains.
214 The non-toxigenic C. difficile isolated in this study also had low rates of antimicrobial 
215 resistance in contrast to previous reports (15). This could be due to the difference in the 
216 time when C. difficile strains were isolated. The AST data in this study was from C. difficile 
217 strains isolated from 2006 – 2015, while a previous study reported AST data on C. difficile 
218 isolated during 2015 (15). This difference in time-frames may have contributed to the 
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219 apparent differences in susceptibility pattern. However, with the exception of 
220 metronidazole, the strains of C. difficile isolated from 2011 – 2015 in this study were not less 
221 susceptible than strains from 2006 – 2010 as shown by a comparison of MIC50 and MIC90 
222 data in Table 6. Another possible explanation is the difference in the study sites. C. difficile 
223 strains in this study came from different levels of healthcare facilities where patients may 
224 have been exposed to fewer antimicrobial agents. The previous study (15) was conducted in 
225 a large tertiary hospital in Bangkok where there is a higher rate of antimicrobial use. 
226 While all C. difficile in this study remained susceptible to metronidazole and 
227 vancomycin, similar to the earlier study (15), there did appear to be some creep in 
228 metronidazole MICs similar to that described by Baines et al. (40). How this increase in 
229 metronidazole MIC may affect the outcome of CDI treatment in Thailand is unknown. 
230 However, despite updates in the international guideline for the treatment of CDI (41), 
231 metronidazole and vancomycin remain the treatment of choice in Thailand. The most recent 
232 clinical study of CDI in Thailand was conducted in 2008 and most patients responded well to 
233 either metronidazole or vancomycin with low mortality and recurrence (37). It should also 
234 be noted that the metronidazole MICs remained low in the previous study, while there was 
235 a slight increase in vancomycin MICs, suggesting that different treatment regimens may 
236 have been used in different hospitals (15). MICs of fidaxomicin were not determined as the 
237 drug is not available in Thailand, however, since fidaxomicin has not been used previously, it 
238 is likely that C. difficile in Thailand remain susceptible to this agent. This was shown in the 
239 previous study which reported low MIC (0.004 – 0.25 mg/L) of fidaxomicin in C. difficile 
240 strains from Bangkok, Thailand in 2015 (15). 
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241 The rates of resistance to clindamycin, erythromycin and moxifloxacin in this study 
242 were similar to the previous study in Thailand (15). Most fluoroquinolone-resistant strains 
243 belonged to C. difficile RT 017, which is also consistent with earlier reports in several 
244 countries (12, 13, 15, 42). For many years, antimicrobial use in Thailand has been loosely 
245 regulated (43), and the misuse of antimicrobials, especially fluoroquinolones in diarrhoeal 
246 patients, is common (44). Fluoroquinolone resistance provides RT 017 with a survival 
247 advantage and this was a factor that led to an outbreak of CDI caused by RT 017 in Ireland 
248 (45, 46). This could also happen in Thailand given that no regulation in antimicrobial usage 
249 has been implemented (47).
250 A limitation of this study is that all C. difficile strains were from an existing collection. 
251 The TH-NIH is a reference laboratory which does not have any records of patients' 
252 information or other diagnostic tests which may have been done in the referring hospital. 
253 Thus, it was impossible to tell whether the strains were from patients with CDI or 
254 asymptomatic carriers. However, the aim of this study was to describe the diversity of 
255 C. difficile strains in Thailand, not the prevalence of CDI in the country nor the characteristics 
256 of patients. Since the TH-NIH had the largest collection of C. difficile from various locations, 
257 it was suitable for this study.
258 Conclusion
259 There was a high prevalence of non-toxigenic C. difficile and C. difficile RT 017 (A-
260 B+CDT-) in Thailand, similar to many countries in South East Asia, suggesting that these 
261 C. difficile strains are endemic to the region. There were also high rates of antimicrobial 
262 resistance among Thai toxigenic C. difficile strains, especially fluoroquinolone resistance in 
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263 RT 017. Given the common misuse of fluoroquinolone in Thailand, there is a significant risk 
264 that an outbreak of CDI caused by RT 017 will occur in this country.
265
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396 Figures and Tables
397
398 Figure 1 – Source of C. difficile strains used in this study. Strains from Bangkok came from 7 
399 different healthcare facilities (number of strains: 11, 4, 2, 2, 1, 1, 1). Strains from other 




402 Figure 2 – PCR product of tcdA gene in different C. difficile strains. (A) Both the non-
403 repeating region (demonstrated by a 252 bp band) and the repeating region (demonstrated 
404 by 193 bp band) of tcdA were present in every A+B+CDT-  C. difficile strains. (B) Only the 
405 non-repeating region of tcdA was present in A-B+CDT- C. difficile strains, indicating a 
406 deletion in the repeating region of tcdA gene. (C) Non-toxigenic C. difficile strains do not 




409 Figure 3 – C. difficile strains with similar ribotyping patterns. (A) C. difficile RT QX 578 (A-B-
410 CDT-) has eight distinct bands with the mirror-image arrangement. (B) An A-B+CDT- C. 
411 difficile strain was classified as RT QX 578. (C) One A+B+CDT- C. difficile strain had a similar 
412 banding pattern to RT QX 578 (RT KI 003). (D) and (E) Two A-B+CDT- C. difficile strains and 
413 (F) one non-toxigenic C. difficile strain had similar ribotyping pattern and were classified into 




416 Table 1 – Ribotypes and toxin gene profiles of C. difficile found in this study.






046, KI 002, KI 003, KI 004, KI 007, KI 009, 













KI 017, KI 005
KI 015, KI 020


















KI 005**, KI 023, KI 027, KI 028, QX 238


















418 Note: * One strain each of ribotypes QX 021 and QX 578 was A-B+CDT- C. difficile.
419 ** Three strains of ribotype KI 005 were A-B+CDT- while two were non-toxigenic.
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420 Table 2 – Distribution of common C. difficile ribotypes in Thailand.
Distribution (%)
Ribotypes





























































































422 Table 3 – Antimicrobial susceptibility for 100 C. difficile strains isolated in Thailand from 









mg/l S I R S I R
Vancomycin † 0.25 – 1 0.5 0.5 ≤ 2 - > 2 100 - 0
Metronidazole † ≤0.125 – 2 0.25 2 ≤ 2 - > 2 100 - 0
Clindamycin ‡ 0.5 – > 256 32 >256 ≤ 2 4 ≥ 8 4 5 91
Moxifloxacin ‡ 1 – 32 2 32 ≤ 2 4 ≥ 8 61 8 31
Levofloxacin 1 – >128 4 128 - - - - - -
Tetracycline ‡ ≤0.125 – 8 2 8 ≤ 4 8 > 16 82 18 0
Erythromycin § ≤0.5 – >128 2 >128 - - > 8 - - 35
Chloramphenicol ‡ ≤0.5 – 64 4 16 ≤ 8 16 > 32 88 4 8
424
425 Note: † MIC breakpoints based on EUCAST recommendation (21)
426 ‡ MIC breakpoints based on CLSI recommendation (20)




429 Table 4 – Summary of MIC data for eight antimicrobials against Thai C. difficile strains by 
430 their toxin gene profiles













Vancomycin 0.5 1 0.5 0.5 0.5 0.5
Metronidazole 0.5 2 0.25 1 1 2
Clindamycin 32 > 256 256 > 256 32 > 256
Moxifloxacin 2 32 16 32 2 16
Levofloxacin 4 > 128 128 128 4 128
Tetracycline 1 8 4 8 1 4
Erythromycin 4 > 128 16 > 128 2 > 128




432 Table 5 – Antimicrobial susceptibility rate of common C. difficile ribotypes in Thailand.
Antimicrobial
Ribotype (n)
Clindamycin Moxifloxacin Tetracycline Chloramphenicol
017 (22) 14% 23% 55% 100%
Other toxigenic ribotypes 
(23)
0% 65% 78% 89%
QX 578 (18) 0% 79% 95% 63%
QX 500 (12) 0% 67% 83% 100%
QX 021 (11) 9% 73% 100% 82%
Other non-toxigenic 
ribotypes (13)




434 Table 6 – Comparison of MIC50/90 between C. difficile strains from 2006 – 10 and 2011 – 15.










MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
Vancomycin 0.5 1 0.5 0.5 0.5 0.5 0.5 0.5
Metronidazole ≤0.125 0.25 0.25 0.25 0.5 2 1 2
Clindamycin 128 > 256 64 > 256 128 > 256 32 > 256
Moxifloxacin 16 32 2 32 4 32 2 32
Levofloxacin 128 128 128 128 8 128 4 128
Tetracycline 4 8 4 8 4 8 0.125 4
Erythromycin 4 > 128 2 > 128 8 > 128 2 256




 Around half of Clostridium difficile strains from Thailand were non-toxigenic.
 The most common strain was tcdA-negative, tcdB-positive ribotype 017.
 20 new C. difficile ribotypes were found.
 There was a slight creep in metronidazole MIC over time.
